July 26th 2022
A comprehensive discussion on factors that inform treatment selection of available AR-targeted therapy for patients with nonmetastatic CRPC.
July 19th 2022
Expert perspectives on monitoring patients with nonmetastatic castration-resistant prostate cancer and deciding when to initiate systemic therapy.
Shared insight on a clinical scenario of a patient with nonmetastatic castration-resistant prostate cancer who was treated with prostatectomy and adjuvant therapy.
July 12th 2022
Closing out their discussion on a clinical scenario of metastatic HSPC, expert panelists consider optimal patient monitoring strategies and novel imaging.
Expert panelists briefly share their excitement for trial data readouts in metastatic hormone-sensitive prostate cancer from the annual ASCO 2022 Annual meeting.
July 5th 2022
Continuing their discussion on frontline AR-targeted therapy in mHSPC, experts define how accessibility and patient eligibility impact treatment selection.
Expert perspectives on frontline AR-targeted therapy in metastatic hormone-sensitive prostate cancer, with deference to recent clinical trial data on triplet therapy.
June 28th 2022
A brief review of the respective roles of multidisciplinary care and genetic testing in patients diagnosed with metastatic hormone-sensitive prostate cancer.
Centering discussion on a clinical scenario of metastatic hormone-sensitive prostate cancer, expert panelists consider how they might approach frontline therapy in this setting.
May 19th 2022
Highlighting ongoing clinical trials in prostate cancer, experts share practical advice on optimal treatment strategies for community physicians.
May 12th 2022
Before closing out their discussion, experts review novel targeted agents under investigation in metastatic CRPC.
Experts share insight on the greatest unmet needs in treating patients with metastatic castration-resistant prostate cancer.
May 5th 2022
Andrew J. Armstrong, MD, MSc, breaks down ongoing prostate cancer clinical trials looking at targeted radioligand therapies.
Oliver Sartor, MD, considers the respective roles of Lu-PSMA-617 and radium-223 as radiotherapy in the setting of mCRPC.
April 28th 2022
Expert perspectives on where Lu-PSMA-617 therapy may fit into the treatment paradigm for metastatic castration-resistant prostate cancer.
A comprehensive review of the design and results of VISION, which analyzed Lu-PSMA-617 therapy in patients with mCRPC.
April 26th 2022
Andrew J. Armstrong, MD, MSc, discusses updated results from the phase 3 ARCHES trial in metastatic hormone-sensitive prostate cancer.
April 21st 2022
Expert Scott Tagawa, MD, MS, FACP, details the role of radium-223 in treating metastatic CRPC and highlights real-world experiences.
Shared insight on the key factors that play into the selection of therapy for patients with metastatic castration-resistant prostate cancer.
April 14th 2022
A detailed review of the available pharmacologic agents used to treat patients with metastatic castration-resistant prostate cancer.